Agios Pharm Stock Investor Sentiment
| AGIO Stock | USD 58.66 0.44 0.74% |
About 57% of Agios Pharm's investor base is looking to short. The analysis of the overall investor sentiment regarding Agios Pharm suggests that many traders are alarmed. Agios Pharm's investing sentiment overview a quick insight into current market opportunities from investing in Agios Pharm. Many technical investors use Agios Pharm stock news signals to limit their universe of possible portfolio assets and to time the market correctly.
Panic Vs Confidence
43
Panic | Confidence |
Today, several news technology companies offer sentiment data to assist traders in manufacturing news sentiment indicators for investment decisions. We partner with these technology firms in helping retail investors build forecasting models that use Agios Pharm's input sentiment indicators derived from textual data and news published on major financial information outlets and social sites. These indicators can be used to analyze time-dependent numerical information representing public perception toward Agios Pharm.
News SentimentBullish | Hype SentimentBearish | Insider SentimentDisposing |
Agios Historical Sentiment
Although Agios Pharm's investment sentiment alone cannot always predict changes in its future share prices, when combined with other fundamental and technical analysis, a better chance to time the market can be gained. Certain informational and emotional events regarding Agios, such as negative comments on social media and news outlets, may cause fear in the market and push Agios Pharm's investors to sell their holdings. The opposite can also be true when favorable news is released; it may translate into optimism and boost the price of Agios.
Agios |
Agios Pharm Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Agios Pharm can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Far too much social signal, news, headlines, and media speculation about Agios Pharm that are available to investors today. That information is available publicly through Agios media outlets and privately through word of mouth or via Agios internal channels. However, regardless of the origin, that massive amount of Agios data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Agios Pharm news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Agios Pharm relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Agios Pharm's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Agios Pharm alpha.
Agios Pharm Performance against Dow Jones
Price Growth (%) |
| Timeline |
1 | Agios to Present at the 2024 Cantor Global Healthcare Conference on September 18, 2024 | 09/05/2024 |
2 | Do Options Traders Know Something About Agios Stock We Dont | 09/27/2024 |
3 | Thermo Fishers Oncomine gains FDA approval as brain tumor diagnostic | 10/21/2024 |
4 | Agios Pharmaceuticals Q3 2024 Earnings Preview | 10/30/2024 |
5 | Agios Pharmaceuticals GAAP EPS of 16.22 beats by 7.53, revenue of 8.96M misses by 0.54M | 10/31/2024 |
6 | Agios Pharmaceuticals Third Quarter 2024 Earnings EPS Beats Expectations, Revenues Lag | 11/01/2024 |
7 | Agios to Present New Data on Mitapivat and Tebapivat in Rare Blood Disorders at 66th ASH Annual Meeting and Exposition | 11/05/2024 |
8 | Disposition of 1500 shares by Ballal Rahul D. of Agios Pharm at 59.21 subject to Rule 16b-3 | 11/08/2024 |
9 | Agios Pharmaceuticals chief legal officer sells 1.14 million in stock | 11/12/2024 |
10 | Disposition of 300 shares by Foster-cheek Kaye I of Agios Pharm at 32.21 subject to Rule 16b-3 | 11/19/2024 |
11 | Is Agios Pharmaceuticals Stock Outpacing Its Medical Peers This Year | 11/26/2024 |
Check out Agios Pharm Hype Analysis, Agios Pharm Correlation and Agios Pharm Performance. To learn how to invest in Agios Stock, please use our How to Invest in Agios Pharm guide.You can also try the Correlation Analysis module to reduce portfolio risk simply by holding instruments which are not perfectly correlated.
Is Biotechnology space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Agios Pharm. If investors know Agios will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Agios Pharm listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share 11.66 | Revenue Per Share 0.582 | Quarterly Revenue Growth 0.212 | Return On Assets (0.18) | Return On Equity 0.5366 |
The market value of Agios Pharm is measured differently than its book value, which is the value of Agios that is recorded on the company's balance sheet. Investors also form their own opinion of Agios Pharm's value that differs from its market value or its book value, called intrinsic value, which is Agios Pharm's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Agios Pharm's market value can be influenced by many factors that don't directly affect Agios Pharm's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Agios Pharm's value and its price as these two are different measures arrived at by different means. Investors typically determine if Agios Pharm is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Agios Pharm's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.